Argus initiated coverage of Edwards Lifesciences (EW) with a Buy rating and $90 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences’ SAPIEN X4 Valve Study: A Potential Game-Changer in Heart Valve Treatment
- Edwards Lifesciences’ PASCAL System: A Promising Solution for Tricuspid Regurgitation
- Edwards Lifesciences’ Pivotal Trial: A Game Changer in Tricuspid Valve Repair?
- Edwards Lifesciences’ PROGRESS Trial: A Game Changer for Aortic Stenosis Treatment?
- Edwards Lifesciences’ PASCAL System Trial: A Potential Game-Changer for Tricuspid Valve Repair